Top

Published in:

Open Access 01-12-2006 | Research article

Transcription factor 7-like 2 (TCF7L2) variant is associated with familial breast cancer risk: a case-control study

Authors: Barbara Burwinkel, Kalai S Shanmugam, Kari Hemminki, Alfons Meindl, Rita K Schmutzler, Christian Sutter, Barbara Wappenschmidt, Marion Kiechle, Claus R Bartram, Bernd Frank

Published in: BMC Cancer | Issue 1/2006

Abstract

Background

The transcription factor 7-like 2 (TCF7L2) is a critical component of the Wnt/β-catenin pathway. Aberrant TCF7L2 expression modifies Wnt signaling and mediates oncogenic effects through the upregulation of c-MYC and cyclin D. Genetic alterations in TCF7L2 may therefore affect cancer risk. Recently, TCF7L2 variants, including the microsatellite marker DG10S478 and the nearly perfectly linked SNP rs12233372, were identified to associate with type 2 diabetes.

Methods

We investigated the effect of the TCF7L2 rs12255372 variant on familial breast cancer (BC) risk by means of TaqMan allelic discrimination, analyzing BRCA1/2 mutation-negative index patients of 592 German BC families and 735 control individuals.

Results

The T allele of rs12255372 showed an association with borderline significance (OR = 1.19, 95% C.I. = 1.01-1.42, P = 0.04), and the Cochran-Armitage test for trend revealed an allele dose-dependent association of rs12255372 with BC risk (P _trend = 0.04).

Conclusion

Our results suggest a possible influence of TCF7L2 rs12255372 on the risk of familial BC.

Nelson WJ, Nusse R: Convergence of Wnt, beta-catenin, and cadherin pathways. Science. 2004, 303: 1483-1487. 10.1126/science.1094291.CrossRefPubMedPubMedCentral

Grant SF, Thorleifsson G, Reynisdottir I, Benediktsson R, Manolescu A, Sainz J, Helgason A, Stefansson H, Emilsson V, Helgadottir A, et al: Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet. 2006, 38: 320-323. 10.1038/ng1732.CrossRefPubMed

van Vliet-Ostaptchouk JV, Shiri-Sverdlov R, Zhernakova A, Strengman E, van Haeften TW, Hofker MH, Wijmenga C: Association of variants of transcription factor 7-like 2 (TCF7L2) with susceptibility to type 2 diabetes in the Dutch Breda cohort. Diabetologia. 2006, Oct 10

Zhang C, Qi L, Hunter DJ, Meigs JB, Manson JE, van Dam RM, Hu FB: Variant of transcription factor 7-like 2 (TCF7L2) gene and the risk of type 2 diabetes in large cohorts of U.S. women and men. Diabetes. 2006, 55: 2645-2648. 10.2337/db06-0643.CrossRefPubMed

Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber T, Mandelker D, Leary RJ, Ptak J, Silliman N, et al: The Consensus Coding Sequences of Human Breast and Colorectal Cancers. Science. 2006, 314: 268-274. 10.1126/science.1133427.CrossRefPubMed

Wong NA, Pignatelli M: Beta-catenin – a linchpin in colorectal carcinogenesis?. Am J Pathol. 2002, 160: 389-401.CrossRefPubMedPubMedCentral

Lin SY, Xia W, Wang JC, Kwong KY, Spohn B, Wen Y, Pestell RG, Hung MC: Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci U S A. 2000, 97: 4262-4266. 10.1073/pnas.060025397.CrossRefPubMedPubMedCentral

Cowin P, Rowlands TM, Hatsell SJ: Cadherins and catenins in breast cancer. Curr Opin Cell Biol. 2005, 17: 499-508. 10.1016/j.ceb.2005.08.014.CrossRefPubMed

Rowlands TM, Pechenkina IV, Hatsell SJ, Pestell RG, Cowin P: Dissecting the roles of beta-catenin and cyclin D1 during mammary development and neoplasia. Proc Natl Acad Sci U S A. 2003, 100: 11400-11405. 10.1073/pnas.1534601100.CrossRefPubMedPubMedCentral

10.

Meindl A, the German Consortium for Hereditary Breast and Ovarian Cancer: Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population. Int J Cancer. 2002, 97: 472-480. 10.1002/ijc.1626.CrossRefPubMed

11.

Frank B, Hemminki K, Wappenschmidt B, Klaes R, Meindl A, Schmutzler RK, Bugert P, Untch M, Bartram CR, Burwinkel B: Variable number of tandem repeats polymorphism in the SMYD3 promoter region and the risk of familial breast cancer. Int J Cancer. 2006, 118: 2917-2918. 10.1002/ijc.21696.CrossRefPubMed

12.

Frank B, Hemminki K, Wirtenberger M, Bermejo JL, Bugert P, Klaes R, Schmutzler RK, Wappenschmidt B, Bartram CR, Burwinkel B: The rare ERBB2 variant Ile654Val is associated with an increased familial breast cancer risk. Carcinogenesis. 2005, 26: 643-647. 10.1093/carcin/bgh342.CrossRefPubMed

13.

Dupont WD, Plummer WD: Power and sample size calculations for studies involving linear regression. Control Clin Trials. 1998, 19: 589-601. 10.1016/S0197-2456(98)00037-3.CrossRefPubMed

14.

Houlston RS, Peto J: The future of association studies of common cancers. Hum Genet. 2003, 112: 434-435.PubMed

15.

Antoniou AC, Easton DF: Polygenic inheritance of breast cancer: Implications for design of association studies. Genet Epidemiol. 2003, 25: 190-202. 10.1002/gepi.10261.CrossRefPubMed

16.

Duval A, Gayet J, Zhou XP, Iacopetta B, Thomas G, Hamelin R: Frequent frameshift mutations of the TCF-4 gene in colorectal cancers with microsatellite instability. Cancer Res. 1999, 59: 4213-4215.PubMed

17.

Duval A, Rolland S, Tubacher E, Bui H, Thomas G, Hamelin R: The human T-cell transcription factor-4 gene: structure, extensive characterization of alternative splicings, and mutational analysis in colorectal cancer cell lines. Cancer Res. 2000, 60: 3872-3879.PubMed

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/6/268/prepub

Title: Transcription factor 7-like 2 (TCF7L2) variant is associated with familial breast cancer risk: a case-control study
Authors: Barbara Burwinkel
Kalai S Shanmugam
Kari Hemminki
Alfons Meindl
Rita K Schmutzler
Christian Sutter
Barbara Wappenschmidt
Marion Kiechle
Claus R Bartram
Bernd Frank
Publication date: 01-12-2006
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2006
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/1471-2407-6-268

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2006

Population attributable risk of breast cancer in white women associated with immediately modifiable risk factors

Gene × Gene interaction between MnSOD and GPX-1 and breast cancer risk: a nested case-control study

Mismatch repair and treatment resistance in ovarian cancer

Increased tartrate-resistant acid phosphatase (TRAP) expression in malignant breast, ovarian and melanoma tissue: an investigational study

Molecular profiling of signalling proteins for effects induced by the anti-cancer compound GSAO with 400 antibodies

Frequent promoter hypermethylation of RASSF1A and CASP8 in neuroblastoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer